Benzinga | Jan 24, 2022 12:44PM EST

Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows

A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ:AZN), Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX), or Johnson & Johnson (NYSE:JNJ) increases antibody levels significantly in those who have previously received two doses of Sinovac Biotech Ltd (NASDAQ:SVA) CoronaVac.

* According to the study, CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants.

* "This study provides important options for policymakers in the many countries where inactivated vaccines ... have been used," said Andrew Pollard, director of the Oxford Vaccine Group and study lead.

* Related: Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron.

* However, another study in December found that Sinovac's two-dose shot followed by a booster dose of Pfizer-BioNTech's vaccine showed a lower immune response against the Omicron variant than other strains.

* The third dose of CoronaVac also increased antibodies, but the results were better when a different vaccine was used, according to the latest study that included 1,240 volunteers in Brazil.

* Antibody levels were low before delivery of the booster doses, with only 20.4% of adults aged 18-60 and 8.9% of adults aged over 60 having detectable levels of neutralizing antibodies.

* These were seen to significantly increase across every booster vaccine regimen, across all groups, 28 days post-vaccination.

* Price Action: SVA shares were trading at $6.47 during the market session on the last check Monday.